After a 2017 in which Merck saw 1% revenue growth, we expect the company to post continued modest revenue growth and adjusted EPS of just above $4 in 2018. We expect the growth to be primarily led by the Oncology and Anti-Infective segments.
After a 2017 in which Merck saw 1% revenue growth, we expect the company to post continued modest revenue growth and adjusted EPS of just above $4 in 2018. We expect the growth to be primarily led by the Oncology and Anti-Infective segments.
Share this Article
Recommended